{"type":"trials","record":{"id":86916,"source_id":"isrctn","external_id":"ISRCTN92166560","title":"A randomised controlled trial of alternative treatments to inhibit VEGF in age-related choroidal neovascularisation","brief_summary":"1. Avastin® (bevacizumab) is not inferior to Lucentis® (ranibizumub) with respect to the benefits of vascular endothelial growth factor (VEGF) inhibition in maintaining/improving visual acuity in eyes with chorodial neovascularisation (CNV). 2. Treatment with VEGF inhibition can be 'safely' withdrawn at 3 months with monthly review to detect CNV reactivation, i.e. criteria for re-starting treatment can be pre-specified to prevent any difference in average visual acuity compared with continuing monthly treatment. More details can be found at http://www.nets.nihr.ac.uk/projects/hta/073601 Protocol can be found at http://www.nets.nihr.ac.uk/__data/assets/pdf_file/0003/51780/PRO-07-36-01.pdf","overall_status":"Completed","phases":["Not Applicable"],"study_type":"Interventional","sponsor":"Royal Group of Hospitals Trust (UK)","enrollment":610,"countries":["United Kingdom","Northern Ireland"],"start_date":"2007-07-01","completion_date":"2012-11-30","last_update_date":"2022-10-24","source_url":"https://www.isrctn.com/ISRCTN92166560","editorial_summary":"A registered Not Applicable study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T03:46:04.814269+00:00","last_seen_at":"2026-09-25T03:46:39.551+00:00","metadata":{"sex":"All","age_range":"Adult","comparator":null,"attribution":"Source: ISRCTN ISRCTN92166560; retrieved 2026-09-25","interventions":["Bevacizumab, ranibizumub","Drug"],"reuse_license":"Registry contribution CC BY 4.0; generated metadata CC0","registry_source":"ISRCTN","outcome_measures":["The primary outcome is corrected 1 metre VAlogMAR, measured as the number of letters read on a standard ETDRS chart. Th…","Secondary outcomes will be analysed after one and two years of follow-up, unless otherwise stated. 1. Frequencies of ad…"],"design_description":"Interventional","source_has_results":false},"controlled_terms":["Age-related macular degeneration (AMD)","Participants, clinical staff and researchers will be masked to allocation of VEGF inhibition drug but not to stopping/c…","results","7-year follow-up","Long-term visual outcomes","Bevacizumab, ranibizumub","Drug"],"relevance_confidence":70,"source_quality_score":98,"freshness_score":50,"publication_state":"published","match_explanation":"Source terminology contains: age-related macular degeneration.","quality_checked_at":"2026-09-25T03:46:42.633202+00:00","duplicate_cluster_key":"id:isrctn92166560","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2007-07-01 to 2012-11-30","comparator":null,"confidence":"structured-source","population":"All · Adult","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T03:46:39.599Z","intervention":["Bevacizumab, ranibizumub","Drug"],"participants":610,"study_design":"Interventional","subject_scope":"Human clinical study registration","evidence_stage":"Not Applicable","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["The primary outcome is corrected 1 metre VAlogMAR, measured as the number of letters read on a standard ETDRS chart. Th…","Secondary outcomes will be analysed after one and two years of follow-up, unless otherwise stated. 1. Frequencies of ad…"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Source terminology contains: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as Interventional."],"matched_fields":["controlled terminology","title context","study type"],"relevance_score":70,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ISRCTN Registry","homepage_url":"https://www.isrctn.com/"}},"canonical_url":"https://www.immortal.life/trials/86916","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}